A problem or defect in the quality of a medicine can have an impact on health and on success of the therapy: to prevent these risks, the involvement of pharmacovigilance becomes indispensable, just as collaboration between the various company functions is essential in the management of information in order to carry out all the activities required from a legislative point of view.
This scenario pushed the AFI Pharmacovigilance Group, on the occasion of the 63rd edition of the Symposium, to plan a session, scheduled for June 6, that will discuss the aspects related to the correlation between quality complaints and impact on patient health.
In particular, through two technical interventions and a round table, the meeting will allow us to discuss the processes, identifying the barriers and possible actions necessary to evaluate the complaint from a qualitative and productive point of view, simultaneously managing the pharmacovigilance activities required by Good Pharmacovigilance Practices (GVP).
Andrea Oliva, Coordinator of the AFI Pharmacovigilance Study Group and moderator of the session “Pharmacovigilance and quality: when a quality complaint has an impact on the patient’s health“, during our interview, introduced the need of pharmacovigilance department to interact with other company functions and the solutions for better management of complaints and their impact on surveillance and supervisory activities.
